Vivo Capital LLC Purchases 174,974 Shares of Savara Inc (NASDAQ:SVRA)

Vivo Capital LLC boosted its holdings in Savara Inc (NASDAQ:SVRA - Free Report) by 9.1% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,088,323 shares of the company's stock after acquiring an additional 174,974 shares during the quarter. Savara comprises approximately 0.8% of Vivo Capital LLC's portfolio, making the stock its 27th biggest holding. Vivo Capital LLC owned about 1.54% of Savara worth $9,815,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in SVRA. SG Americas Securities LLC purchased a new stake in Savara during the 3rd quarter worth about $140,000. Bank of New York Mellon Corp boosted its position in Savara by 20.6% during the third quarter. Bank of New York Mellon Corp now owns 261,435 shares of the company's stock worth $988,000 after acquiring an additional 44,641 shares during the last quarter. Jennison Associates LLC grew its stake in Savara by 44.6% in the 3rd quarter. Jennison Associates LLC now owns 3,866,762 shares of the company's stock worth $14,616,000 after acquiring an additional 1,192,730 shares during the period. Principal Financial Group Inc. acquired a new position in Savara in the 3rd quarter valued at $48,000. Finally, Jump Financial LLC purchased a new position in shares of Savara during the 3rd quarter worth $123,000. Hedge funds and other institutional investors own 87.93% of the company's stock.

Analyst Ratings Changes

A number of brokerages have issued reports on SVRA. Piper Sandler raised their price target on Savara from $7.00 to $16.00 and gave the stock an "overweight" rating in a research note on Monday, March 4th. JMP Securities reissued a "market outperform" rating and issued a $8.00 target price on shares of Savara in a research report on Monday. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $8.20.

Savara Trading Up 1.6 %

Shares of Savara stock traded up $0.08 during trading hours on Thursday, reaching $5.07. The stock had a trading volume of 585,837 shares, compared to its average volume of 871,234. The company has a current ratio of 15.66, a quick ratio of 15.66 and a debt-to-equity ratio of 0.19. Savara Inc has a 1 year low of $1.86 and a 1 year high of $5.70. The firm has a market capitalization of $700.56 million, a price-to-earnings ratio of -15.36 and a beta of 0.73. The firm has a 50 day simple moving average of $4.89 and a two-hundred day simple moving average of $4.52.

Savara (NASDAQ:SVRA - Get Free Report) last released its quarterly earnings data on Thursday, March 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.02. As a group, equities research analysts anticipate that Savara Inc will post -0.38 earnings per share for the current year.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.